Illuminating Pathways in Epithelial-Driven Inflammation

Program Description

Join us for a dynamic Mechanisms to Medicine symposium featuring expert panelists Drs. Joseph Han, Flavia Hoyte, and Nizar Jarjour as they examine evolving management approaches for epithelial cytokine–driven inflammatory diseases of the upper and lower airways. This program brings together multidisciplinary perspectives from pulmonology, allergy and immunology, and otorhinolaryngology to explore shared underlying disease mechanisms in asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). 

The engaging faculty panel will guide participants through an examination of epithelial cytokine signaling in airway diseases and practical therapeutic decision-making involving new and emerging biologic therapies that target these shared upstream mechanisms. Through a focused Whiteboard animation, case-based checkpoints, and interactive faculty dialogue, learners will examine how epithelial alarmins such as thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33) drive inflammation, airway dysfunction, and disease persistence. 

Attendees will also learn about the latest clinical evidence for newer and emerging biologic therapies that target upstream epithelial cytokine signaling and discuss how to incorporate these novel therapies into mechanism-based treatment strategies, with an emphasis on optimizing disease control, reducing oral corticosteroid use, and improving outcomes across the unified airway.

Target Audience

This educational activity has been designed to educate pulmonologists, clinical immunologists/allergists, and ear, nose, and throat [ENT] specialists who manage patients with epithelial-driven inflammatory airway diseases.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

1. Explain the pathogenesis of epithelial-driven inflammatory airway diseases, including implications for the treatment of asthma, CRSwNP, and COPD
2. Discuss the clinical profiles and evidence for biologic therapies that target epithelial cytokines in the treatment of epithelial-driven inflammatory airway diseases
3. Incorporate biologic medications into therapeutic regimens for epithelial-driven inflammatory airway diseases to address underlying pathophysiologic processes, improve disease control, and reduce oral corticosteroid use

Program Agenda

7:00 PM  Preactivity Questionnaire and Faculty Introductions

7:10 PM Early Signaling in Inflammatory Airway Diseases

7:25 PM  Advances in the Management of Severe Asthma

7:40 PM Applying a Mechanism-Based Framework to Inflammatory Diseases of the Upper Airways

7:55 PM   A New Era in COPD Management: Here Come the Biologics

8:15 PM Key Takeaways, Recap, Postactivity Questionnaire, and Q&A Session

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation. 

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Americans With Disabilities Act

Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas at info@exchangecme.com to discuss their specific needs.

Integritas Contact Information

For information about this program, please contact us at info@exchangecme.com.